Streetbeat News

Regulatory

BA

EADSY

Airbus SE (OTC:EADSY) reported a 12% increase in aircraft deliveries during Q1, reaching 142 aircraft, aligning with Q1 2022 levels but falling short of its own expectations by about six planes. Despite challenges, including seat shortages for wide-body jets and delivery delays for the A321, Airbus aims for 800 deliveries in 2024. Boeing Co (NYSE:BA) faces production constraints due to regulatory issues. Airbus will update on its delivery performance on April 9.

Portfolio Pulse from Shivani Kumaresan

April 03, 2024 | 2:29 pm

TSLA

Tesla Inc (NASDAQ:TSLA) plans to scout locations in India for a new EV plant, focusing on states with automotive manufacturing or ports for export. The company intends to invest $2 billion to $3 billion in the factory. This move aligns with India's policy to lower import tariffs for automakers committing to local production within three years. Tesla is also constructing a plant in Mexico for a future lower-priced vehicle.

Portfolio Pulse from Anan Ashraf

April 03, 2024 | 1:42 pm

ABAT

American Battery Technology Company (ABTC) has been awarded a $20M tax credit by the U.S. DOE to support its battery recycling facility's expansion in Nevada. This award, part of the Qualifying Advanced Energy Project Credits program, will fund capital expenditures and equipment for ABTC's commercial scale recycling operations. ABTC's innovative recycling process aims to recover battery materials efficiently and with a low environmental impact. This funding complements over $70M in previous U.S. DOE grants, furthering ABTC's efforts to establish a domestic battery metals supply chain and support workforce development in Nevada.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 1:17 pm

SPRY

ARS Pharmaceuticals has submitted a response to the FDA's Complete Response Letter (CRL) for neffy, addressing all additional requests including positive data from a repeat dose PK/PD study and updated testing showing no measurable nitrosamine levels. The submission triggers a review period of up to six months by the FDA.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 1:04 pm

SPY

Fed's Bostic, in a CNBC interview, indicated a cautious approach towards adjusting economic policies amidst stable inflation and employment. He acknowledged the bumpy road ahead but emphasized not rushing to disrupt the economy's dynamics as long as inflation trends towards the target rate. Bostic also noted that current contacts have not raised concerns about employment, suggesting a watchful but steady stance on policy adjustments.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 1:03 pm

SPY

Fed's Bostic, in a CNBC interview, indicated a more patient approach to monetary policy, forecasting a single rate cut in Q4 this year. He expects inflation to decrease incrementally through 2024, not returning to the 2% target until 2026.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 1:02 pm

SPY

Fed's Bostic commented on CNBC that the economy is maintaining its strong momentum, with any weakening being very incremental. He believes that over a longer period, the economy needs to slow to reach its longer-run potential. Bostic is optimistic that growth can continue while inflation gradually decreases, albeit more slowly than expected.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 1:02 pm

VNDA

Vanda Pharmaceuticals Inc's (NASDAQ:VNDA) Fanapt (iloperidone) tablets received FDA approval for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. This approval expands Fanapt's market, previously approved for schizophrenia treatment since 2009. Bipolar disorder affects approximately 2.8% of the U.S. adult population, with a significant portion classified as severe. The approval was based on a pivotal study showing statistically significant improvement in patients treated with Fanapt over placebo. Despite this positive development, Vanda's net product sales for 2023 decreased by 4% Y/Y, with sales of another major drug, Hetlioz, declining due to increased competition. VNDA shares surged 27.9% in premarket trading following the announcement.

Portfolio Pulse from Vandana Singh

April 03, 2024 | 12:48 pm

GNPX

Genprex is expanding its clinical trial sites for the Acclaim-3 clinical study, which tests Reqorsa Therapy in combination with Tecentriq for treating small cell lung cancer. This expansion is in collaboration with a large network of community-based oncology practices. The Acclaim-3 study has received support from the FDA in the form of Orphan Drug and Fast Track Designations.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:32 pm

SYRA

Syra Health announced that its 'Syrenity' research study protocol has been approved by the Institutional Review Board. This approval marks a significant milestone for the company, potentially advancing its position in health research and development.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:20 pm